Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) are non-selective cation channels that function as critical polymodal sensors in the peripheral nervous system. They are predominantly co-expressed in nociceptive sensory neurons, where they integrate a variety of noxious stimuli including extreme temperatures, acidic pH, and chemical irritants like capsaicin (TRPV1) and mustard oil (TRPA1). Their activation triggers the influx of calcium and sodium, leading to action potential generation and the release of pro-inflammatory neuropeptides such as substance P and CGRP, which drive neurogenic inflammation. Beyond their role in acute and chronic pain, these channels are involved in the pathophysiology of respiratory diseases like asthma and chronic cough, as well as gastrointestinal and dermatological conditions. While they are distinct proteins, their functional interlinking has led to the development of dual antagonists aimed at providing superior analgesic efficacy compared to single-target inhibitors. However, clinical progress has been complicated by side effects such as hyperthermia and impaired thermal sensitivity, particularly associated with TRPV1 modulation.
Antagonism of cation influx to prevent neuronal firing; Agonism followed by prolonged channel desensitization to deplete neuropeptides.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential vanilloid 1 and Transient receptor potential ankyrin 1 (TRPV1 and TRPA1).